Antidepressant-like actions of DOV 21,947: A "triple" reuptake inhibitor

European Journal of Pharmacology

Volumn 461, Issue 2-3, 2003, Pages 99-104

  Skolnick, Phil ^a   Popik, Piotr ^b   Janowsky, Aaron ^c   Beer, Bernard ^a   Lippa, Arnold S ^a  

^a DOV Pharmaceutical Inc   (United States)

^b INSTITUTE OF PHARMACOLOGY   (Poland)

^c PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

"Broad spectrum" antidepressant; 5 HT (5 hydroxytryptamine, serotinin); Dopamine; DOV 21,947; Norepinephrine; Reuptake inhibitor

Indexed keywords

1 (3,4 DICHLOROPHENYL) 3 AZABICYCLO[3.1.0]HEXANE; 3BETA (4 IODOPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; ANTIDEPRESSANT AGENT; BICYCLO COMPOUND; CARRIER PROTEIN; DESIPRAMINE; DOPAMINE; DOPAMINE UPTAKE INHIBITOR; DOV 21 947; FLUOXETINE; IMIPRAMINE; NOMIFENSINE; NORADRENALIN; NORADRENALIN UPTAKE INHIBITOR; RECOMBINANT PROTEIN; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; TRITIUM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BINDING ASSAY; BINDING COMPETITION; CELL LINE; CELL MEMBRANE; COMPETITIVE INHIBITION; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; FORCED SWIMMING TEST; HUMAN; HUMAN CELL; IC 50; IMMOBILIZATION; LOCOMOTION; MALE; MOTOR ACTIVITY; NEUROTRANSMITTER UPTAKE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

EID: 12244291291     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(03)01310-4     Document Type: Article

References (34)

1. Ainsworth K., Smith S.E., Zetterstrom T.S., Pei Q., Franklin M., Sharp T. Effect of antidepressant drugs on dopamine D1 and D2 receptor expression and dopamine release in the nucleus accumbens of the rat. Psychopharmacology. 140:1998;470-477.
2. Borsini F., Meli A. Is the forced swim test a suitable model for revealing antidepressant activity? Psychopharmacology. 94:1988;147-160.
3. Boukoms A., Mangini L. Pergolide: an antidepressant adjuvant for mood disorders? Psychopharmacol. Bull. 29:1993;207-211.
4. Briley M., Moret C. Antidepressant properties of specific serotonin-noradrenaline reuptake inhibitors. Skolnick P. Antidepressants: New Pharmacological Strategies. 1997;35-52 Humana Press, Totowa.
5. Corrigan M.H., Denahan A.Q., Wright C.E., Ragual R.J., Evans D.L. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress. Anxiety. 11:2000;58-65.
6. D'Aquila P.S., Collu M., Gessa G.L., Serra G. The role of dopamine in the mechanism of action of antidepressant drugs. Eur. J. Pharmacol. 405:2000;365-373.
7. Dziedzicka Wasylewska M., Rogoz R., Klimek V., Maj J. Repeated administration of antidepressant drugs affects the levels of mRNA coding for D1 and D2 dopamine receptors in the rat brain. J. Neural Transm. 104:1997;515-524.
8. Eshleman A.J., Henningsen R.A., Neve K.A., Janowsky A. Release of dopamine via the human transporter. Mol. Pharmacol. 45:1994;312-316.
9. Eshleman A.J., Neve R.L., Janowsky A., Neve K.A. Characterization of a recombinant human dopamine transporter in multiple cell lines. J. Pharmacol. Exp. Ther. 274:1995;276-283.
10. Eshleman A.J., Carmolli M., Cumbay M., Martens C.R., Neve K.A., Janowsky A. Characteristics of drug interactions with recombinant biogenic amine transporters expressed in the same cell type. J. Pharmacol. Exp. Ther. 289:1999;877-885.
11. Galli A., DeFelice L.J., Duke B.D., Moore K.R., Blakely R.D. Sodium-dependent norepinephrine-induced currents in norepinephrine-transporter-transfected HEK-293 cells blocked by cocaine and antidepressants. J. Exp. Biol. 198:1995;2197-2212.
12. Huthmann E., Juza M. Modification of a commercial chiral stationary phase: influences on enantiomer separation using simulated moving bed chromatography. J. Chromatogr., A. 908:2000;185-200.
13. Izumi T., Inoue T., Kitagawa N., Nishi N., Shimanaka S., Takahashi Y., Kusumi I., Odagaki Y., Denda K., Ohmori T., Koyama T. Open pergolide treatment of tricyclic and heterocyclic antidepressant-resistant depression. J. Affect. Disord. 61:2000;127-132.
14. Kent J.M. SNaRIs, NASSAs, and NaRIs: new agents for the treatment of depression. Lancet. 355:2000;911-918.
15. Lammers C.H., Diaz J., Schwartz J.C., Sokoloff P. Selective increase of dopamine D3 receptor gene expression as a common effect of chronic antidepressant treatments. Mol. Psychiatry. 5:2000;378-388.
16. Layer R.T., Popik P., Olds T., Skolnick P. Antidepressant-like actions of the polyamine site NMDA antagonist, eliprodil (SL-82.0715). Pharmacol. Biochem. Behav. 52:1995;621-627.
17. Naranjo C., Tremblay L.K., Busto U.E. The role of the brain reward system in depression. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 25:2001;781-823.
18. Paul I.A. Excitatory amino acid signalling, major depression and the actions of antidepressants. Pharm. News. 8:2001;33-44.
19. Porsolt R.D., Lenegre A. Behavioral models of depression. Elliott J.M., Heal D.J., Marsden C.A. Experimental Approaches to Anxiety and Depression. 1992;73-85 Wiley, London.
20. Porsolt R.D., Le Pichon M., Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature. 266:1977;730-732.
21. Porsolt R.D., Anton G., Blavet N., Jalfre M. Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur. J. Pharmacol. 47:1978;379-391.
22. Ramamoorthy S., Bauman A.L., Moore K.B., Han H., Yang-Feng T., Chang A.S., Ganapathy V., Blakely R.D. Antidepressant- and cocaine-sensitive human serotonin transporter: molecular cloning, expression, and chromosomal localization. Proc. Natl. Acad. Sci. U. S. A. 90:1993;2542-2546.
23. Serra G., Argiolas A., Klimek V., Fadda F., Gessa G.L. Chronic treatment with antidepressant prevents the inhibitory effect of small doses of aopmorphine on dopamine synthesis and motor activity. Life Sci. 25:1979;414-424.
24. Sitland-Marken P.A., Wells B.G., Froemming J.H., Chu C.C., Brown C.S. Psychiatric applications of bromocriptine. J. Clin. Psychiatry. 51:1990;68-82.
25. Skolnick P. Antidepressants: New Pharmacological Strategies. 1997;Humana Press, Totowa.
26. Skolnick P. Antidepressants beyond monoamine-based therapies: clues to new approaches. J. Clin. Psychiatry. 63:2002;19-23.
27. Skolnick P., Krystal J.H. Depression. Lodge D., Danysz W., Parsons C.G. Therapeutic Potential of Ionotropic Glutamate Receptor Antagonists and Modulators. 2002;71-90 F.P. Graham Publishing, Johnson City.
28. Skolnick P., Legutko B., Li X., Bymaster F.P. Current perspectives on the development of non-biogenic amine based antidepressants. Pharmacol. Res. 43:2001;411-423.
29. Sporn J., Ghaemi S.N., Sambur M.R., Rankin M.A., Recht J., Sachs G.S., Rosenbaum J.F., Fava M. Pramipexole augmentation in the treatment of unipolar and bipolar depression: a retrospective chart review. Ann. Clin. Psychiatry. 12:2000;137-140.
30. Steru L., Chermat R., Theirry B., Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology. 85:1985;367-370.
31. Vetulani J., Nalepa I. Antidepressants: past, present and future. Eur. J. Pharmacol. 405:2000;351-363.
32. Willner P. Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation. Psychopharmacology. 134:1997;319-329.
33. Willner P. Dopaminergic mechanisms in depression and mania. Watson S. Psychopharmacology: The Fourth Generation of Progress. 2000;Lippincott Williams & Wilkins, New York. On-line edition.
34. Zacharko R.M., Anisman H. Stressor-induced anhedonia in the mesocorticolimbic system. Neurosci. Biobehav. Rev. 15:1991;391-405.